{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:34:52Z","timestamp":1791999292902,"version":"4.4.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pharma.2026.03.006","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:06:42Z","timestamp":1775315202000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nitrosamine impurities: Critical insights into chemistry, analytical tools, and worldwide regulatory requirements"],"prefix":"10.1016","author":[{"given":"Aditya","family":"Umrethwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucha","family":"Mutalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3662-4635","authenticated-orcid":false,"given":"Sanjay","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2026.03.006_bib0395","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1021\/acs.jmedchem.0c02120","article-title":"Critical analysis of drug product recalls due to nitrosamine impurities","volume":"64","author":"Bharate","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharma.2026.03.006_bib0400","unstructured":"Information Note. Nitrosamine impurities. https:\/\/www.who.int\/news\/item\/20-11-2019-information-note-nitrosamine-impurities. Accessed 7 Nov 2023."},{"key":"10.1016\/j.pharma.2026.03.006_bib0405","unstructured":"NDMA, a contaminant found in multiple drugs, has industry seeking sources and solutions. https:\/\/cen.acs.org\/pharmaceuticals\/pharmaceutical-chemicals\/NDMA-contaminant-found-multiple-drugs\/98\/i15. Accessed 6 Nov 2023."},{"key":"10.1016\/j.pharma.2026.03.006_bib0410","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jsps.2022.12.010","article-title":"An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals","volume":"31","author":"Wichitnithad","year":"2023","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.pharma.2026.03.006_bib0655","first-page":"519","article-title":"Influence of disulfiram on the metabolism of N-nitrosodiethylamine","author":"Frank","year":"1984","journal-title":"IARC Sci Publ"},{"key":"10.1016\/j.pharma.2026.03.006_bib0660","unstructured":"Nitrosamines \u2013 Update from the CEP procedure - European Directorate for the Quality of Medicines & HealthCare. https:\/\/www.edqm.eu\/en\/-\/nitrosamines-update-from-the-cep-procedure. Accessed 7 Nov 2023."},{"key":"10.1016\/j.pharma.2026.03.006_bib0665","unstructured":"Ranitidine (Zantac) recall expanded, many questions remain - Harvard Health. https:\/\/www.health.harvard.edu\/blog\/ranitidine-zantac-recall-expanded-many-questions-remain-2020040218044. Accessed 7 Nov 2023."},{"key":"10.1016\/j.pharma.2026.03.006_bib0670","unstructured":"Metformin Recall: NDMA Contamination. https:\/\/www.health.com\/condition\/type-2-diabetes\/metformin-recall. Accessed 7 Nov 2023."},{"key":"10.1016\/j.pharma.2026.03.006_bib0675","unstructured":"Biba E. (2010) General chapter <1469> Nitrosamine impurities."},{"key":"10.1016\/j.pharma.2026.03.006_bib0415","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.xphs.2022.12.022","article-title":"Regulatory experiences with root causes and risk factors for nitrosamine impurities in pharmaceuticals","volume":"112","author":"Horne","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2026.03.006_bib0420","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","article-title":"Formation of N-nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies","volume":"27","author":"Cioc","year":"2023","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.pharma.2026.03.006_bib0425","doi-asserted-by":"crossref","first-page":"114677","DOI":"10.1016\/j.jpba.2022.114677","article-title":"Nitrites as precursors of N-nitrosation in pharmaceutical samples \u2013 A trace level analysis","volume":"213","author":"Jire\u0161","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2026.03.006_bib0430","doi-asserted-by":"crossref","first-page":"114872","DOI":"10.1016\/j.jpba.2022.114872","article-title":"N-Nitrosation in the absence of nitrosating agents in pharmaceuticals?","volume":"218","author":"Jire\u0161","year":"2022","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2026.03.006_bib0680","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1248\/cpb.c21-00289","article-title":"N-Nitrosodimethylamine (NDMA) Formation from Ranitidine Impurities: Possible Root Causes of the Presence of NDMA in Ranitidine Hydrochloride","volume":"69","author":"Yokoo","year":"2021","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.pharma.2026.03.006_bib0455","first-page":"1","article-title":"Regulatory updates and analytical methodologies for nitrosamine impurities detection in sartans, ranitidine, nizatidine, and metformin along with sample preparation techniques","volume":"52","author":"Shaik","year":"2020","journal-title":"Crit Rev Anal Chem"},{"key":"10.1016\/j.pharma.2026.03.006_bib0685","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.1021\/es500997e","article-title":"Formation mechanism of NDMA from ranitidine, trimethylamine, and other tertiary amines during chloramination: A computational study","volume":"48","author":"Liu","year":"2014","journal-title":"Environ Sci Technol"},{"key":"10.1016\/j.pharma.2026.03.006_bib0435","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1208\/s12249-019-1376-1","article-title":"Lesson learnt from recall of valsartan and other angiotensin II receptor blocker drugs containing NDMA and NDEA impurities","volume":"20","author":"Charoo","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.pharma.2026.03.006_bib0480","author":"Hill"},{"key":"10.1016\/j.pharma.2026.03.006_bib0485","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/cpt.2652","article-title":"Rifampin drug\u2013drug\u2013interaction studies: reflections on the nitrosamine impurities issue","volume":"113","author":"van Haarst","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharma.2026.03.006_bib0690","unstructured":"CDER Nitrosamine Impurity Acceptable Intake Limits _ FDA."},{"key":"10.1016\/j.pharma.2026.03.006_bib0695","unstructured":"Medicines Agency E. Lessons learnt from presence of N-nitrosamine impurities in sartan medicines."},{"key":"10.1016\/j.pharma.2026.03.006_bib0700","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","article-title":"Formation of N-nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies","volume":"27","author":"Cioc","year":"2023","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.pharma.2026.03.006_bib0705","doi-asserted-by":"crossref","first-page":"114132","DOI":"10.1016\/j.jpba.2021.114132","article-title":"On-line solid phase extraction-ultra-high performance liquid chromatography coupled to tandem mass spectrometry for the determination of N-nitrosodiethanolamine in baby shampoo","volume":"202","author":"Tada","year":"2021","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2026.03.006_bib0710","doi-asserted-by":"crossref","first-page":"116303","DOI":"10.1016\/j.jpba.2024.116303","article-title":"Investigation into the genotoxic impurity, 1-methyl-4-nitrosopiperazine, in rifampicin","volume":"248","author":"Tian","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2026.03.006_bib0465","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jpba.2018.11.010","article-title":"NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines","volume":"164","author":"Parr","year":"2019","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2026.03.006_bib0475","unstructured":"sitagliptin recall tga - Google Search. https:\/\/www.google.com\/search?q=sitagliptin+recall+tga&rlz=1C1GCEU_enIN1037IN1037&oq=sita&gs_lcrp=EgZjaHJvbWUqCAgAEEUYJxg7MggIABBFGCcYOzIGCAEQRRg5MgwIAhAAGEMYsQMYigUyCggDEC4YsQMYgAQyCQgEEAAYQxiKBTIPCAUQABgUGIcCGLEDGIAEMgkIBhAAGEMYigUyBggHEEUYPNIBCDMzMDJqMGo3qAIAsAIA&sourceid=chrome&ie=UTF-8. Accessed 4 Nov 2023."},{"key":"10.1016\/j.pharma.2026.03.006_bib0495","unstructured":"Fda, Cder Combined N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) Impurity Assay by GC\/MS-Headspace."},{"key":"10.1016\/j.pharma.2026.03.006_bib0490","unstructured":"FDA Updates and Press Announcements on Nitrosamine in Varenicline (Chantix) | FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-nitrosamine-varenicline-chantix. Accessed 4 Nov 2023."},{"key":"10.1016\/j.pharma.2026.03.006_bib0505","unstructured":"Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of NDMA in Metformin Drug Substance and Drug Product."},{"key":"10.1016\/j.pharma.2026.03.006_bib0510","unstructured":"A pharma mystery: Cancer-causing impurities drive joint search for answers | PharmaVoice. https:\/\/www.pharmavoice.com\/news\/pharmaceutical-impurities-nitrosamines\/622244\/. Accessed 7 Nov 2023."},{"key":"10.1016\/j.pharma.2026.03.006_bib0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105459","article-title":"Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: Learnings from N-nitrosamine case studies","volume":"143","author":"Felter","year":"2023","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.pharma.2026.03.006_bib0520","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1021\/acs.chemrestox.3c00083","article-title":"Computational Prediction of Metabolic \u03b1-Carbon Hydroxylation Potential of N-Nitrosamines: Overcoming Data Limitations for Carcinogenicity Assessment","volume":"36","author":"Chakravarti","year":"2023","journal-title":"Chem Res Toxicol"},{"key":"10.1016\/j.pharma.2026.03.006_bib0440","unstructured":"Information about Nitrosamine Impurities in Medications | FDA. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/information-about-nitrosamine-impurities-medications. Accessed 27 Oct 2023."},{"key":"10.1016\/j.pharma.2026.03.006_bib0470","unstructured":"Quinapril | Therapeutic Goods Administration (TGA). https:\/\/www.tga.gov.au\/news\/safety-alerts\/quinapril. Accessed 4 Nov 2023."},{"key":"10.1016\/j.pharma.2026.03.006_bib0450","first-page":"260","article-title":"A brief review on nitrosamine impurity in pharmaceuticals","volume":"10","author":"Patel","year":"2021","journal-title":"J Pharm Sci Biosci Res"},{"key":"10.1016\/j.pharma.2026.03.006_bib0460","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/CRD.0000000000000323","article-title":"Nitrosamine impurities in angiotensin receptor blockers","volume":"28","author":"Shephard","year":"2020","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.pharma.2026.03.006_bib0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.106026","article-title":"NDMA analytics in metformin products: Comparison of methods and pitfalls","volume":"168","author":"Fritzsche","year":"2022","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.pharma.2026.03.006_bib0720","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.18203\/2320-6012.ijrms20204273","article-title":"Metformin and nitrosamine impurities","volume":"8","author":"P.V.","year":"2020","journal-title":"Int J Res Med Sci"},{"key":"10.1016\/j.pharma.2026.03.006_bib0500","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1021\/acsomega.1c00982","article-title":"Development of a sensitive headspace gas chromatography-mass spectrometry method for the simultaneous determination of nitrosamines in losartan active pharmaceutical ingredients","volume":"6","author":"Wichitnithad","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.pharma.2026.03.006_bib0625","unstructured":"Sarah Nexus Genotoxic Impurity Evaluation _ Lhasa Limited."},{"key":"10.1016\/j.pharma.2026.03.006_bib0730","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.xphs.2022.11.024","article-title":"A GC-MS\/MS Method for Trace Level Quantification of Six Nitrosamine Impurities (NDMA, NDEA, NEIPA, NDIPA, NDPA, and NDBA) in Commercially Used Organic Solvents: Dichloromethane, Ethyl Acetate, Toluene, and O-xylene","volume":"112","author":"Kosuri","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2026.03.006_bib0735","unstructured":"Fda, Cder Combined Headspace N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), and N-Nitrosodiisopropylamine (NDIPA) Impurity Assay by GC-MS\/MS."},{"key":"10.1016\/j.pharma.2026.03.006_bib0740","unstructured":"Fda, Cder Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of Six Nitrosamine Impurities in ARB Drugs."},{"key":"10.1016\/j.pharma.2026.03.006_bib0745","unstructured":"Fda, Cder Development and validation of a RapidFire-MS\/MS method for screening of nitrosamine carcinogen impurities N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), N-Nitrosodiisopropylamine (NDIPA), N-Nitrosodibutylamine (NDBA) and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) in ARB drugs."},{"key":"10.1016\/j.pharma.2026.03.006_bib0750","unstructured":"Fda, Cder Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of NDMA in Ranitidine Drug Substance and Drug Product."},{"key":"10.1016\/j.pharma.2026.03.006_bib0755","unstructured":"Fda, Cder Liquid Chromatography-Tandem Mass Spectrometry (LC-MS\/MS) Method for the Determination of NDMA in Ranitidine Drug Substance and Solid Dosage Drug Product."},{"key":"10.1016\/j.pharma.2026.03.006_bib0765","unstructured":"Fda Liquid Chromatography-Electrospray Ionization-High Resolution Mass Spectrometry (LC-ESI-HRMS) Method for the Determination of Nitrosamine Impurities in Metformin Drug Substance and Drug Product."},{"key":"10.1016\/j.pharma.2026.03.006_bib0640","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.xphs.2023.03.022","article-title":"N-nitrosamine mitigation with nitrite scavengers in oral pharmaceutical drug products","volume":"112","author":"Bayne","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2026.03.006_bib0645","doi-asserted-by":"crossref","first-page":"042","DOI":"10.53294\/ijfcpr.2023.3.1.0052","article-title":"Nitrosamine impurities in pharmaceutical dosage forms: Current challenges and mitigation strategies","volume":"3","author":"Dakhole","year":"2023","journal-title":"Int J Front Chem Pharm Res"},{"key":"10.1016\/j.pharma.2026.03.006_bib0525","unstructured":"Fda, Cder, DeantonisDM (2018) M7(R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk Guidance for Industry."},{"key":"10.1016\/j.pharma.2026.03.006_bib0530","doi-asserted-by":"crossref","DOI":"10.1021\/acs.oprd.3c00100","article-title":"The Nitrosamine \u201cSaga\u201d: Lessons Learned from Five Years of Scrutiny","author":"Nudelman","year":"2023","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.pharma.2026.03.006_bib0535","series-title":"Toxicity of Nitrosamines: Their Possible Human Health Hazards","author":"Magee","year":"1971"},{"key":"10.1016\/j.pharma.2026.03.006_bib0540","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/jat.4574","article-title":"A systematic review on multipotent carcinogenic agent, N-nitrosodiethylamine (NDEA), its major risk assessment, and precautions","volume":"44","author":"Janmeda","year":"2024","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.pharma.2026.03.006_bib0545","article-title":"Risk assessment of N-nitrosamines in food","volume":"21","author":"Schrenk","year":"2023","journal-title":"EFSA J"},{"key":"10.1016\/j.pharma.2026.03.006_bib0550","doi-asserted-by":"crossref","first-page":"111538","DOI":"10.1016\/j.cbi.2025.111538","article-title":"Comparative DNA damage induced by eight nitrosamines in primary human and macaque hepatocytes","volume":"416","author":"Seo","year":"2025","journal-title":"Chem Biol Interact"},{"key":"10.1016\/j.pharma.2026.03.006_bib0555","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.3390\/ijms23094559","article-title":"Metabolic activation and DNA interactions of carcinogenic N-nitrosamines to which humans are commonly exposed","volume":"23","author":"Li","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pharma.2026.03.006_bib0560","unstructured":"DTSEM - Salt Lake Technical Center O N-nitrosodiethanolamine (NDELA)."},{"key":"10.1016\/j.pharma.2026.03.006_bib0565","doi-asserted-by":"crossref","first-page":"116303","DOI":"10.1016\/j.jpba.2024.116303","article-title":"Investigation into the genotoxic impurity, 1-methyl-4-nitrosopiperazine, in rifampicin","volume":"248","author":"Tian","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.pharma.2026.03.006_bib0570","unstructured":"Step. Committee for Human Medicinal Products ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. 2015."},{"key":"10.1016\/j.pharma.2026.03.006_bib0575","unstructured":"Step. Committee for Human Medicinal Products ICH guideline Q9 on quality risk management. 2015."},{"key":"10.1016\/j.pharma.2026.03.006_bib0580","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.xphs.2022.12.022","article-title":"Regulatory experiences with root causes and risk factors for nitrosamine impurities in pharmaceuticals","volume":"112","author":"Horne","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2026.03.006_bib0585","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","article-title":"The Nitrosamine \u201cSaga\u201d: Lessons Learned from Five Years of Scrutiny","volume":"27","author":"Nudelman","year":"2023","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.pharma.2026.03.006_bib0590","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/acs.oprd.0c00264","article-title":"Controlling a cohort: use of mirabilis-based purge calculations to understand nitrosamine-related risk and control strategy options","volume":"24","author":"Burns","year":"2020","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.pharma.2026.03.006_bib0595","doi-asserted-by":"crossref","first-page":"9793","DOI":"10.1021\/es301867b","article-title":"Measurement of nitrosamine and nitramine formation from no x reactions with amines during amine-based carbon dioxide capture for postcombustion carbon sequestration","volume":"46","author":"Dai","year":"2012","journal-title":"Environ Sci Technol"},{"key":"10.1016\/j.pharma.2026.03.006_bib0600","doi-asserted-by":"crossref","DOI":"10.1021\/acs.oprd.3c00073","article-title":"A consideration of the extent that tertiary amines can form N-nitroso dialkylamines in pharmaceutical products","author":"Ashworth","year":"2023","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.pharma.2026.03.006_bib0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2023.10.001","article-title":"Revisiting the landscape of potential small and drug substance related nitrosamines in pharmaceuticals","author":"Burns","year":"2023","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.pharma.2026.03.006_bib0610","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1021\/acs.oprd.0c00323","article-title":"Pathways for N-nitroso compound formation: secondary amines and beyond","volume":"24","author":"L\u00f3pez-Rodr\u00edguez","year":"2020","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.pharma.2026.03.006_bib0780","unstructured":"FDA sets acceptable intake limits for nitrosamines in drugs | RAPS. https:\/\/www.raps.org\/News-and-Articles\/News-Articles\/2023\/8\/FDA-sets-acceptable-intake-limits-for-nitrosamines. Accessed 6 Nov 2023."},{"key":"10.1016\/j.pharma.2026.03.006_bib0615","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1208\/s12249-023-02523-w","article-title":"Nitroso impurities in drug products: an overview of risk assessment, regulatory milieu, and control strategy","volume":"24","author":"Charoo","year":"2023","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.pharma.2026.03.006_bib0620","unstructured":"DEREK Nexus The discovery of N-Nitrosamine impurities."},{"key":"10.1016\/j.pharma.2026.03.006_bib0635","first-page":"100645","article-title":"N-nitrosamines in processed meats: Exposure, formation and mitigation strategies","volume":"13","author":"Xie","year":"2023","journal-title":"J Agric Food Res"},{"key":"10.1016\/j.pharma.2026.03.006_bib0650","doi-asserted-by":"crossref","first-page":"105762","DOI":"10.1016\/j.yrtph.2024.105762","article-title":"Control of N-nitrosamine impurities in drug products: Progressing the current CPCA framework and supporting the derivation of robust compound specific acceptable intakes","volume":"156","author":"Ponting","year":"2025","journal-title":"Regul Toxicol Pharmacol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:40:02Z","timestamp":1776771602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450926000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":72,"alternative-id":["S0003450926000441"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2026.03.006","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nitrosamine impurities: Critical insights into chemistry, analytical tools, and worldwide regulatory requirements","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2026.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}